RT Journal Article
T1 Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons
A1 Rey, Pablo
A1 López-Real, A.
A1 Sánchez Iglesias, Sofía
A1 Muñoz, Ana
A1 Soto-Otero, Ramón
A1 Labandeira García, José Luis
K1 Angiotensin
K1 Basal ganglia
K1 Dopamine
K1 Neuroprotection
K1 NAD(P)H-oxidase
K1 Parkinson's disease
K1 Oxidative stress
K1 6-Hydroxydopamine
AB Angiotensin II activates (via type 1 receptors) NAD(P)H-dependent oxidases, which are a major source of superoxide, and is relevant in the pathogenesis of several cardiovascular diseases and certain degenerative changes associated with ageing. Given that there is a brain renin–angiotensin system and that oxidative stress is a key contributor to Parkinson's disease, we investigated the effects of angiotensin II and angiotensin type 1 (AT1) receptor antagonists in the 6-hydroxydopamine model of Parkinson's disease. Rats subjected to intraventricular injection of 6-hydroxydopamine showed bilateral reduction in the number of dopaminergic neurons and terminals. Injection of angiotensin alone did not induce any significant effect. However, angiotensin increased the toxic effect of 6-hydroxydopamine. Rats treated with the AT1 receptor antagonist ZD 7155 and then 6-hydroxydopamine (with or without exogenous administration of angiotensin) showed a significant reduction in 6-hydroxydopamine-induced oxidative stress (lipid peroxidation and protein oxidation) and dopaminergic degeneration. Dopaminergic degeneration was also reduced by the NAD(P)H inhibitor apocynin. Angiotensin may play a pivotal role, via AT1 receptors, in increasing the oxidative damage of dopaminergic cells, and treatment with AT1 antagonists may reduce the progression of Parkinson's disease.
PB Elsevier
YR 2007
FD 2007
LK http://hdl.handle.net/10347/32468
UL http://hdl.handle.net/10347/32468
LA eng
NO Neurobiology of Aging, Volume 28, Issue 4, 2007, Pages 555-567
DS Minerva
RD 24 abr 2026